Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ERIC 2018 | CLL cell dynamics

Nicholas Chiorazzi • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

Nicholas Chiorazzi, MD, of the Feinstein Institute of Medical Research, Manhasset, NY, discusses the dynamics of chronic lymphocytic leukemia (CLL) cells with us at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Nicholas Chiorazzi

Identifying new CLL therapeutic targets by focusing on the evolution of cancer cells
1:00
Identifying new CLL therapeutic targets by focusing on the evolution of cancer cells
Nicholas Chiorazzi • 7 Oct 2022
Leukemic cell birth rate & the role of recently divided B cells in CLL
2:49
Leukemic cell birth rate & the role of recently divided B cells in CLL
Nicholas Chiorazzi • 7 Oct 2022
Obstacles to achieving a cure in CLL
1:02
Obstacles to achieving a cure in CLL
Nicholas Chiorazzi • 7 Oct 2022
Updates on cellular and molecular interactions in the CLL microenvironment
3:56
Updates on cellular and molecular interactions in the CLL microenvironment
Nicholas Chiorazzi • 18 Sep 2021

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Nicholas Chiorazzi • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Nicholas Chiorazzi • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Nicholas Chiorazzi • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Nicholas Chiorazzi • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals